What is the risk of persistent and evolving bacteria in an era of high diphtheria vaccination coverage?

Similar documents
A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

EUVAC.NET A surveillance network for vaccine-preventable diseases

Diphtheria infections caused by the different toxigenic biotypes of Corynebacterium diphtheriae

Measles and rubella monitoring January 2015

Critical immunity thresholds for measles elimination

University of Warwick institutional repository:

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

Global Measles and Rubella Update November 2018

EURO POLIO PAGE Data as of 04 October 2005 (Week 38)

Global Measles and Rubella Update. April 2018

Characterization and comparison of invasive Corynebacterium diphtheriae isolates from France. and Poland

Global Measles and Rubella Update October 2018

TB, BCG and other things. Chris Conlon Infectious Diseases Oxford

Highlighting in the WHO European Region: measles outbreaks rubella surveillance acute flaccid paralysis surveillance

Highlighting in the WHO European Region: Summary. No. 21(February 2012)

Hepatitis A SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Monthly measles and rubella monitoring report

Influenza Update N 157

Monitoring vaccine-preventable diseases is

GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights

Summary. Primary care data. Week 49/2014. Season

European monthly measles monitoring (EMMO)

Diphtheria: are we ready for it?

Main developments in past 24 hours

Influenza Weekly Surveillance Report

Influenza Update N 176

World Health Organization Regional Office for Europe Surveillance of measles and rubella Data as of 15 March 2006

Global reductions in measles mortality and the risk of measles resurgence

The State of Measles and Rubella in the WHO European Region

Shigellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Polio Eradication and Surveillance. December

Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

Whole genome sequencing & new strain typing methods in IPC. Lyn Gilbert ACIPC conference Hobart, November 2015

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

Guidance for Travelers on Temporary Work Assignment Abroad

Highlighting in the WHO European Region:

Invasive meningococcal disease

Multidrug-resistant Tuberculosis - World, Europe, Switzerland

Enhancing animal health security and food safety in organic livestock production

Drug resistance TB in People Living with HIV: research questions and priorities.

Update on Progress and Challenges in Achieving Measles and Rubella Targets

Diphtheria Outbreak in KZN. Prashini Moodley KZN Department of Health College of Health Sciences, UKZN

Benefits of the pneumococcal immunisation programme in children in the United Kingdom

COMMISSION OF THE EUROPEAN COMMUNITIES REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

Where we stand in EFORT

Meningitis January Dr Andrew Lee Consultant in Communicable Disease Control, PHE Information in this slide set was correct as of 21.1.

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

New genomic typing method MLST

Invasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland

Vaccinations pre- and posttransplant. Burkhard Tönshoff, MD, PhD University Children s Hospital Heidelberg, Germany

Progress Toward Measles Elimination in the Russian Federation,

Weekly influenza surveillance overview

THE CARE WE PROMISE FACTS AND FIGURES 2017

HPAI H5(N8) in Member States in poultry, captive and wild birds

Controlling Vaccine Preventable Diseases in the US and Global Immunization Efforts

Situation update in the European Region: overview of influenza surveillance data week 40/2009 to week 07/2010.

OVERVIEW OF CURRENT IDENTIFICATION SYSTEMS AND DATABASES

What is this document and who is it for?

Epidemiological Update Diphtheria

Overview of drug-induced deaths in Europe - What does the data tell us?

Humanitarian Initiative to Prepare for a Pandemic Influenza Emergency (HIPPIE) Ron Waldman, MD Avian and Pandemic Influenza Unit USAID/Washington

Appendix A: Disease-Specific Chapters

CND UNGASS FOLLOW UP

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

3.1 PHASE 2 OF THE GLOBAL PROJECT

Global Immunizations & UNICEF s Role Dr. Robin Nandy Principal Advisor & Chief of Immunizations UNICEF Headquarters

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

Implications of the Diphtheria Epidemic in the Former Soviet Union for Immunization Programs

D.A.Henderson, MD, MPH. Professor of Medicine, University of Pittsburgh Honorary Fellow, London School of Hygiene and Tropical Medicine

Alcohol-related harm in Europe and the WHO policy response

#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)

Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva

Global MDR-TB Update GIDC. Paul Nunn, MA, FRCP(UK) Director, Global Infectious Disease Consulting London, UK

Campylobacter: the actual status and control options

TETANUS, DIPHTHERIA, PERTUSSIS (Td/Tdap)

Global EHS Resource Center

The Economics of Tobacco Control and Tobacco Taxation: Challenges & Opportunities for a Tobacco Free Turkey

HEV Update Blood Components. Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden)

Drug Prices Report Opioids Retail and wholesale prices * and purity levels,by drug, region and country or territory (prices expressed in US$ )

Table 7.1 Summary information for lung cancer in Ireland,

European status report on alcohol and health Leadership, awareness and commitment

Recommended composition of influenza virus vaccines for use in the influenza season

Drug-resistant Tuberculosis

TETANUS, DIPHTHERIA, WHOOPING COUGH (Td/Tdap)

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017

Main conclusions and options for response

Mathematical modelling approach to estimating TB burden in children Pete Dodd (University of Sheffield) & James Seddon (Imperial College London)

Immunisation Update for Occupational Health

WINTER SEASON 2016/17 MORTALITY SUMMARY REPORT FROM THE EUROMOMO NETWORK

New guidelines for the management of norovirus outbreaks in acute and community health and social care settings

The cancer burden in the European Union and the European Region: the current situation and a way forward

Activities in 2010, Priorities for 2011

O c t o b e r 1 0,

Resurgent diphtheria - are we safe?

Giardiasis (lambliasis)

Transcription:

What is the risk of persistent and evolving bacteria in an era of high diphtheria vaccination coverage? Dr. Natasha S. Crowcroft Chief, Infectious Diseases, Public Health Ontario, Canada, Associate Professor, University of Toronto Heather Rilkoff (PHO), Joanne White (PHE), Professor Androulla Efstratiou (PHE) Fondation Mérieux 26 th November 2013

Full disclosure I have no conflicts of interest to declare Membership of the National Advisory Committee on Immunization (Canada), the International Expert Committee on the Elimination of Measles, Rubella and Congenital Rubella Syndrome, Pan American Health Organization (PAHO) of the World Health Organization (WHO), and the Measles and Rubella Working Group of the Strategic Advisory Group of Experts (SAGE) WHO 2

Outline Background Methods for literature review Disease, organism and current epidemiology Lessons from the Epidemic in the Former Soviet Union (FSU) Non-toxigenic and zoonotic strains - implications Conclusions 3

Methods for literature review Review of literature - Medline and Embase MESH terms. Diphtheria Toxin or Diphtheria or Corynebacterium diphtheriae combined with the following : Drug Resistance, Multiple, Bacterial or Microbial Sensitivity Tests or Drug Resistance, Bacterial Evolution Carrier State Disease Outbreaks or Disease Reservoirs or Disease Transmission, Infectious Genetic Variation or Genomic Instability or Genotype Electrophoresis or Electrophoresis, gel, pulsed-field Zoonoses 4

1 article identified by hand-searching Methods for literature review Article inclusion criteria: Primary focus on diphtheria, biological evolution, persistent or emerging infection, or changes in disease. Medline and Embase (509 articles retrieved) 473 articles excluded following title and abstract 36 articles selected for full text review review 16 articles excluded criteria following full text review 21 articles included in analysis 5

Diphtheria Organism: Corynebacterium diphtheriae and C.ulcerans, virulent strains produce toxin (toxigenic) Gram positive, fermentative, pleomorphic rod C diphtheriae has four biovars, gravis, mitis, intermedius, belfanti (all may produce lethal exotoxin, belfanti less often) Distribution: worldwide, mainly children, very rare in countries with effective childhood immunisation programme Source: Nose or throat of human case or carrier through close contact with infected secretions. In tropics through infected skin lesions. C.ulcerans: raw milk, cattle, cats, dogs Potential for eradication? No

Clinical picture Copyright American Academy of Pediatrics http://www.vaccineinformation.org/photos/diphaap002.jpg Courtesy of Centers for Disease Control and Prevention http://www.vaccineinformation.org/photos/diphiac001.jpg

Chronic non-healing rolled-edge ulcers with base covered by hard, grey adherent membrane Usually in travellers returning from tropics Often follow insect bites Staph and strep commonly isolated as well Toxic manifestations rare As infectious as respiratory diphtheria - possibly more so Cutaneous diphtheria signs/symptoms www.vaccineinformation.org/photos/diphcdc003a.jpg Courtesy of Centers for Disease Control and Prevention

Diphtheria toxin Diphtheria genome is very stable, indicating changes through gene gain/loss and nucleotide substitution (versus intragenic reshuffling) No microbial factors distinguish epidemic from non-epidemic strains apart from toxin production (Mokrousov 2009) Other pathogenic and virulence factors exist Non-toxigenic strains can cause invasive disease, but not epidemics C.ulcerans can be toxigenic but does not cause epidemics Diphtheria toxin A subunit is highly conserved; B subunit has more variability Selection advantage may be through increasing transmission of the organism 9

Current epidemiology of diphtheria 2012 global figures 4,489 reported cases and 2500 estimated deaths (in 2011) 83% estimated DTP3 coverage - 32% of countries reached >=80% DTP3 coverage in all districts High coverage countries Virtually no cases, persistent non-toxigenic strains, possible increase in diversity of stains Re-introduction can lead to clonal outbreaks, and possible transfer of toxin to local strains Low coverage countries Continuous circulation in some regions 10

India 2525 Indonesia 1192 Iran 150 Nepal 138 Lao People's Democratic Republic 130 Pakistan 98 Somalia 65 Thailand 63 Myanmar 19 Sudan 18 Bangladesh 16 Angola 15 Viet Nam 12 Diphtheria cases reported to WHO by country, 2012 Germany 9 Eritrea 8 Latvia 8 Russian Federation 5 Ukraine 5 Iraq 3 Namibia 2 Sweden 2 Belgium 1 Canada 1 Congo 1 Madagascar 1 Netherlands 1 Turkmenistan 1 USA 1 11

12 http://www.who.int/immunization_ monitoring/diseases/diphtheria/en/

Deaths Diphtheria, cases and deaths England and Wales, 1914-2012 80000 Routine vaccination 8000 70000 Notifications 7000 Notifications 60000 50000 40000 30000 Deaths 6000 5000 4000 3000 20000 2000 10000 1000 0 1914 1924 1934 1944 1954 1964 1974 1984 1994 2004 Year * notifications up to 1985, laboratory confirmed cases 1986-2012 Courtesy of Public Health England https://www.gov.uk/government/organisations/public-health-england 0

Immunity to diphtheria in adults is quite low despite good control 100% Percent of sera with antitoxin => 0.1 iu/ml 90% 80% Men Women % immune 70% 60% 50% 40% 30% 20% 10% 0% 15-34 yrs 35-54 yrs 55 yrs+ 2862 samples collected from 6 PHLs in England, 1991 Maple PA et al Vaccine 2000

Typing methods Multilocus Sequence Typing (MLST) becoming the standard (used in 2/8 EU centres in 2010) Ribotyping offers good discrimination reproducibility (used in 6/8 EU centres in 2010) Other methods: Pulsed-field gel electrophoresis (PFGE), Random amplification of polymorphic DNA (RAPD), Amplified fragment length polymorphism (AFLP), Multilocus enzyme electrophoresis (MEE), Spoligotyping, Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry Application relies on good public health laboratorysurveillance, partnerships and expertise in lab diagnosis (WHO, ELWGD, Dipnet, EDSN (European Diphtheria Surveillance Network) De Zoysa et al J Clin Micro 2008; Mokrousov Inf Gen Evol 2009; ECDC EQA diphtheria 15 diagnostics report 2010, WHO Recommendations for vaccine seed lots 2012

Diphtheria in Former Soviet Union (FSU) 1990-1997 45000 40000 35000 30000 Russia other NIS 25000 20000 15000 10000 5000 0 1990 1991 1992 1993 1994 1995 1996 1997

Increased adult susceptibility Increased susceptibility of children Origins of FSU epidemic was not vaccine-driven evolution Inadequate information of physicians and the public (false contraindications for vaccine Dissolution of the Soviet Union leading to socioeconomic problems, delays in control measures, damaged health infrastructure, large population movements Role of the military not routinely immunized; demobilization of 100,000 troops in 1988-89 Vaccine effectiveness remained high 17

Patterns of FSU outbreak Pre-epidemic period simultaneous presence of many different electrophoretic types (ETs) In 1970s to 80s (peak 1983) biotype changed from gravis to mitis By 1990s gravis was predominant, but mitis also found Epidemic clonal group had a unique PFGE profile and comprised MEE-defined ET8 complex strains of D1 (Sankt Petersburg) or D4 ribotypes (Rossija) regardless of their biotype Consistent with introduction of new strain, emergence of strain and/or acquisition of toxin by non-toxigenic strains 18

Distribution of (A) Ribotypes and (B) Electrophoretic types in Russia 1985-97 Popovic et al JID 2000 19

Geographic distribution of ribotypes in Russia 1985-2000 (De Zoysa et al 2008 J Clin Micro) Ribotypes D4 and D7 were documented in Russia before the epidemic; D7 was predominant. During the epidemic D1 and D4 accounted for >80% isolates 20

Impact of restoring vaccine programs: Evolution of organism post-epidemic in FSU: Belarus In Belarus changes occurred in the predominant types between 1996-2005 as the epidemic waned C.diphtheriae biovar gravis was replaced by mitis, and toxigenic strains fell from 47.1% to 5.8% of isolates. D1 (Sankt Petersburg) fell from 24.3 to 2.3%; D4 (Rossija) increased from 25.1 to 49.1% Non-toxigenic isolates with D10 (Cluj) and D4 (Rossija) ribotypes increased to 49.3 and 30.1% Kolodkina et al BMC Infect Dis 2006 21

Lessons learnt from European postepidemic carriage study C.diphtheriae Toxigenic (per 10,000) Non-toxigenic (per 10,000) Estonia N=4505 Latvia N=2480 Lithuania N=2988 Turkey N=2771 0 8 7 0 0 2 28 13 40 4 UK N=8551 Carriage of toxigenic strains is very rare in countries where diphtheria has been controlled (zero in Bulgaria, Finland, Greece, Italy, Ireland) Isolation of non-toxigenic strains may be more likely in countries that are also identifying toxigenic strains 2 isolates in Lithuania were non-toxigenic toxin gene-bearing (NTTB) Wagner et al Clin Microbiol Infect 2010 22

Toxigenic C.diphtheriae persist in atrisk populations/environments Dendrogram of 68 strains collected from 8 countries in 5 regions shows 3 clusters: Russian/NIS ET8 cluster Australian cluster from 1992 US and Canadian (Ontario) isolates from patients and carriers, 1973-96 clearly distinct from Russian/NIS isolates and more diverse both phenotypically and genotypically. Clustering of older and more recent isolates suggests that an endemic focus may have persisted for >25 years Popovic JID 2000, Marston et al J Clin Micro 2001 23

Non-toxigenic strains in countries with high vaccine coverage Risk factors include homelessness, alcoholism, injecting drug use, diabetes mellitus, skin infections, poor dental hygiene. UK: Ribotyping found a single strain never associated with toxigenicity (Reacher et al 2000). Upward trend probably due to increased ascertainment. Exclusively found in throat, >25% associated with beta haemolytic streptococci No evidence of reversion/acquisition of toxigenicity Italy: Non-toxigenic strains isolated in Italy, distinct ribotypes from Russian/NIS strains (Von Hunolstein J Med Micro 2003) Canada: Invasive clone identified in urban poor in Vancouver (Romney et a J Clin Micro 2006). Poland: Increase in non-toxigenic single clone (Zasada et al IJID 2010) 24

42 Non-toxigenic invasive strains in France, New Caledonia, Poland typed by MLST Farfour et al J Clin Micro 2011 Diverse: 11 STs Geographically predominant, for varying time periods Strains in Poland ST8 same as FSU epidemic 25

Zoonotic diphtheria - a potential reservoir? Increasing identification of C.ulcerans case reports, no epidemic potential, mostly zoonotic transmission, only possible person to person transmission reported Toxigenic strains in UK 1986-2008 Wagner K et al Epidemiol Infect 2010 26

Conclusions What is the risk of persistent and evolving bacteria in an era of high diphtheria vaccination coverage? 100% Could vaccine-derived selective pressure be contributing to emergence? Vaccine effectiveness remains high Epidemics have not occurred where vaccine coverage is high Increased non-toxigenic strains and C.ulcerans - greater ascertainment? Toxin is necessary but not sufficient (C.ulcerans) for epidemic potential May underline the importance of understanding determinants of transmission as well as virulence 27

28